Artificial intelligence is moving quickly from pilot projects to everyday use across Indian healthcare, and the pace of that transition has surprised even some industry observers. Total AI expenditure in India is expected to reach 11.78 billion dollars by 2025 and could add as much as one trillion dollars to the Indian economy by FY35. Within healthcare specifically, the AI market is projected to expand from 14.6 billion dollars in 2023 to a striking 102.7 billion dollars by FY28, a growth trajectory that would place healthcare among the most AI intensive sectors in the entire Indian economy.
What makes this shift particularly significant is that it is not confined to a single use case. AI is being applied simultaneously to clinical diagnostics, hospital operations, insurance processing, and drug discovery, meaning its cumulative impact on the sector is likely to be broader than in industries where AI adoption tends to concentrate in one function.
AI inside the hospital: diagnostics and imaging
This growth is visible on the ground in the form of new hospital infrastructure being built with AI as a core design consideration rather than an afterthought. Iswarya Hospital, a new twelve storey facility launched in Chennai, features fourteen operational rooms and seventy two clinical service departments, equipped with AI powered CT and MRI machines, a catheterisation lab, advanced surgical interventions, and specialised therapies in cardiology, orthopaedics, and neurology. Hospitals of this scale are increasingly treating AI as a core part of clinical infrastructure rather than an add on, using it to flag anomalies in imaging faster, prioritise urgent cases, and reduce the time between a scan being taken and a radiologist confirming a diagnosis.
This kind of AI assisted diagnostic support does not replace the radiologist or the treating physician, but it does change the workflow meaningfully, allowing specialists to focus their attention on the cases most likely to need it, while routine or clearly normal scans move through the system faster.
AI is speeding up insurance claims
Insurance is another area where AI is having an immediate, measurable impact, and arguably one where the benefit to ordinary patients is most directly felt. As of 2024, automation and AI tools allow Indian insurers to instantly process up to 70 percent of simple health insurance claims, dramatically reducing turnaround times for patients and easing the administrative burden on insurers. For a patient who has just been discharged from hospital, the difference between waiting days for a claim to clear and having it processed within hours is not a minor convenience, it can materially affect their financial stress during an already difficult period.
As health insurance penetration continues to rise across India, driven partly by the GST exemption now applied to individual health insurance premiums, this kind of claims processing efficiency will only become more important, since insurers will need to handle a rapidly growing volume of claims without a proportional increase in manual processing staff.
Investors are backing health tech aggressively
Health tech start ups are also capturing significant investor attention, a signal that the market sees durable, long term value in this space rather than short term hype. In January 2025, Innovaccer raised 275 million dollars in a Series F funding round to scale its Healthcare Intelligence Cloud, building new AI and cloud capabilities such as copilots and agents for clinical decision support and utilisation management, while expanding its developer ecosystem and deepening collaboration with its network of more than 130 healthcare customers. More broadly, Indian health tech start ups received 828 million dollars in funding in the first half of 2025 alone, a sign of continued investor confidence across the sector, not just in a single standout company.
Where AI adoption still faces real challenges
It is worth being candid that AI adoption in Indian healthcare is not without friction. Data privacy and security remain significant considerations, particularly as more patient data flows through cloud based AI systems. Regulatory frameworks are still catching up to the pace of technological change, and questions around liability, when an AI assisted diagnosis turns out to be wrong, remain areas that the industry and policymakers are actively working through. There is also a practical challenge around training healthcare workers to trust and effectively use AI tools rather than either over relying on them or dismissing them outright. None of these challenges appear to be slowing overall investment or adoption, but they are shaping how responsibly and how quickly different organisations move.
What is next for AI in Indian healthcare
Looking ahead, the most interesting developments are likely to come from AI systems that work across the full patient journey rather than in isolated pockets, connecting diagnostic support, treatment recommendation, insurance processing, and follow up care into a more seamless experience. As the underlying infrastructure, including the Ayushman Bharat Digital Mission's health record registries, continues to mature, AI tools will have access to richer, more longitudinal patient data, which tends to make predictive and diagnostic models considerably more useful.
How AI is being used in drug discovery and pharmaceutical research
Beyond hospital diagnostics and insurance processing, AI is also beginning to reshape pharmaceutical research and development within India, an area that receives less public attention but could prove just as significant over the long term. Traditional drug discovery is notoriously slow and expensive, often taking a decade or more from initial research to a marketable product, with a large proportion of candidate compounds failing at various stages of testing. AI models trained to predict molecular behaviour and potential drug interactions can help researchers narrow down promising candidates far earlier in the process, reducing the number of compounds that need to proceed to expensive and time consuming laboratory and clinical testing.
Given that India's pharmaceutical exports are projected to grow substantially over the coming decades, AI accelerated research and development could become an important competitive differentiator for Indian pharmaceutical companies looking to move up the value chain from primarily generic drug manufacturing toward more original research and specialty drug development, a shift that would meaningfully change the nature of India's pharmaceutical export story.
How hospitals should evaluate AI vendors and tools
For hospital administrators evaluating AI tools, whether for diagnostic imaging support, clinical decision support, or operational efficiency, a few practical questions tend to separate genuinely useful tools from ones that generate more hype than value. It is worth asking how the AI model was trained, and specifically whether it was trained and validated on data that reflects the patient population it will actually be used on, since a model trained primarily on data from one population can perform noticeably worse when applied to a different one. It is also worth understanding how the tool handles edge cases and uncertain results, since a good clinical AI tool should clearly flag when its confidence is low rather than presenting every output with the same apparent certainty. Finally, integration with existing hospital systems matters enormously in practice, since even an excellent AI tool provides limited value if it requires clinical staff to work around a clunky, disconnected interface rather than fitting naturally into their existing workflow.
Building patient trust in AI assisted care
Alongside the technical and regulatory considerations, patient trust remains an important factor that hospitals and technology providers cannot afford to overlook. Many patients still feel more comfortable knowing that a human doctor made the final call on their diagnosis or treatment plan, even when an AI tool contributed meaningfully to that decision. Hospitals that have successfully integrated AI tools without eroding patient trust tend to be transparent about how the technology is used, framing it clearly as a support tool for their doctors rather than a replacement for clinical judgement, and ensuring patients always have the opportunity to discuss results and next steps directly with a physician rather than receiving an AI generated output in isolation.
Frequently asked questions
How big is the AI in healthcare market in India expected to become?
India's AI in healthcare market is projected to grow from 14.6 billion dollars in 2023 to approximately 102.7 billion dollars by FY28.
How is AI currently being used in Indian hospitals?
AI is being used for diagnostic imaging support, including AI powered CT and MRI analysis, as well as for surgical planning, clinical decision support, and hospital operations management.
How is AI changing health insurance in India?
AI and automation now allow Indian insurers to instantly process up to 70 percent of simple health insurance claims, significantly reducing turnaround times for patients.
Which Indian health tech companies have raised significant AI funding?
Innovaccer raised 275 million dollars in a Series F round in January 2025 to expand its AI powered Healthcare Intelligence Cloud, and Indian health tech start ups collectively raised 828 million dollars in the first half of 2025.
What challenges does AI adoption face in Indian healthcare?
Key challenges include data privacy and security, evolving regulatory frameworks, questions around clinical liability, and the need to properly train healthcare workers to use AI tools effectively.
Key takeaways
AI is no longer an experimental technology in Indian healthcare, it is becoming embedded across diagnostics, hospital operations, and insurance processing, backed by both government investment and strong private capital flows into health tech start ups. Whether it is faster diagnosis, smarter claims processing, or predictive tools that help hospitals manage capacity, AI is steadily becoming part of the operational backbone of Indian healthcare, not just a talking point at industry conferences.
